ANN ARBOR, Mich., June 19, 2017 /PRNewswire/ -- NanoBio
Corporation today announced the progression of a novel intranasal
anthrax vaccine into a pre-clinical IND-enabling toxicology study
funded by the U.S. National Institute of Health's National
Institute of Allergy and Infectious Diseases (NIAID). The vaccine
combines NanoBio's novel intranasal nanoemulsion (NE) adjuvant with
recombinant protective antigen (rPA) for anthrax from Porton
Biopharma Ltd (PBL). Following the pre-clinical toxicology study,
the vaccine will progress to a Phase 1 clinical trial.
The advanced development of the vaccine candidate is the result
of a modification to PBL's existing NIAID contract
(#HHSN272201600045C), which totals more than $24 million throughout its eight-year term if all
options are exercised. The modification, valued at $5.6 million, supports further research of the
vaccine components and technologies that accelerate the immune
responses for use in post-event settings following the intentional
release of the Category A priority pathogen Bacillus anthracis, the
bacterium that causes the disease anthrax. Under the contract,
NanoBio, PBL and Public Health England are partnering to produce a
more effective vaccine than the currently licensed injectable
product, by enabling immunity to be achieved in fewer doses and via
intranasal delivery.
"Based on studies completed in the primary animal challenge
model for anthrax, our vaccine offers the potential to enhance
immunity with fewer doses and easier administration," said
David Peralta, chief executive
officer of NanoBio. "Our partnership with PBL and Public Health
England—clear leaders in the field of anthrax vaccine research and
development—is critical to efficiently progressing our intranasal
NE-rPA vaccine candidate to human clinical trials."
Anthrax is caused by the spore-forming bacterium Bacillus
anthracis, and most commonly infects wild and domestic animals.
Anthrax occurs in humans when they are either exposed to infected
animals or to the organism directly, which could occur following a
bioterrorist attack. In humans, the mortality of untreated
cutaneous anthrax ranges up to 25 percent, but increases to nearly
100 percent in inhalational and intestinal cases. The currently
available vaccination schedule for anthrax consists of three
primary injections at zero, one, and six months, two booster doses
at months twelve and eighteen, and then followed by annual boosters
for prolonged protection. Epidemiological evidence indicates the
current vaccine may cause acute side effects and may only provide
partial protection from certain strains.
About NanoBio
Headquartered in Ann Arbor, Michigan, NanoBio®
Corporation is a privately-held biopharmaceutical company focused
on developing and commercializing vaccines and anti-infective
treatments derived from its patented NanoStat® technology platform.
The company's NanoStat® vaccine technology employs a novel
oil-in-water nanoemulsion (NE) that can incorporate, deliver and
adjuvant multiple antigen types. The NE adjuvant is effective when
administered via intranasal or intramuscular vaccination. When
applied intranasally, NE vaccines elicit both mucosal and systemic
immunity.
NanoBio is currently developing NE vaccines for several
respiratory and sexually transmitted diseases, including RSV,
pertussis, pandemic influenza, anthrax, prophylactic and
therapeutic HSV-2, and chlamydia.
For more information on NanoBio or its products, please visit
www.nanobio.com.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/nanobio-and-porton-biopharma-receive-approval-to-advance-next-generation-anthrax-vaccine-300475795.html
SOURCE NanoBio Corporation